Details for New Drug Application (NDA): 206047
✉ Email this page to a colleague
The generic ingredient in PITAVASTATIN CALCIUM is pitavastatin calcium. There are fifteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the pitavastatin calcium profile page.
Summary for 206047
| Tradename: | PITAVASTATIN CALCIUM |
| Applicant: | Zydus Pharms |
| Ingredient: | pitavastatin calcium |
| Patents: | 0 |
Pharmacology for NDA: 206047
| Mechanism of Action | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Suppliers and Packaging for NDA: 206047
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| PITAVASTATIN CALCIUM | pitavastatin calcium | TABLET;ORAL | 206047 | ANDA | Zydus Pharmaceuticals USA Inc. | 68382-481 | 68382-481-16 | 90 TABLET in 1 BOTTLE (68382-481-16) |
| PITAVASTATIN CALCIUM | pitavastatin calcium | TABLET;ORAL | 206047 | ANDA | Zydus Pharmaceuticals USA Inc. | 68382-482 | 68382-482-16 | 90 TABLET in 1 BOTTLE (68382-482-16) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 1MG BASE | ||||
| Approval Date: | Feb 22, 2023 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 2MG BASE | ||||
| Approval Date: | Feb 22, 2023 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 4MG BASE | ||||
| Approval Date: | Feb 22, 2023 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
